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Abstract
Rationale Pharmacokinetics of melatonin in children might
differ from that in adults.
Objectives This study aims to establish a dose–response
relationship for melatonin in advancing dim light melatonin
onset (DLMO), sleep onset (SO), and reducing sleep onset
latency (SOL) in children between 6 and 12 years with
chronic sleep onset insomnia (CSOI).
Methods The method used for this study is the randomized,
placebo-controlled double-blind trial. Children with CSOI
(n=72) received either melatonin 0.05, 0.1, and 0.15 mg/kg
or placebo during 1 week. Sleep was assessed with log and
actigraphy during this week and the week before. Outcomes
were the shifts in DLMO, SO, and SOL.
Results Treatment with melatonin significantly advanced
SO and DLMO by approximately 1 h and decreased SOL
by 35 min. Within the three melatonin groups, effect size
was not different, but the circadian time of administration
(TOA) correlated significantly with treatment effect on
DLMO (rs=−0.33, p=0.022) and SO (rs=−0.38, p=0.004),
whereas clock TOA was correlated with SO shift (r=−0.35,
p=0.006) and not with DLMO shift.
Conclusions No dose–response relationship of melatonin
with SO, SOL, and DLMO is found within a dosage range
of 0.05–0.15 mg/kg. The effect of exogenous melatonin on
SO, SOL, and DLMO increases with an earlier circadian
TOA. The soporific effects of melatonin enhance the SO
shift. This study demonstrates that melatonin for treatment
of CSOI in children is effective in a dosage of 0.05 mg/kg
given at least 1 to 2 h before DLMO and before desired
bedtime.
Keywords Melatonin treatment.Elementary school-aged
children.Chronic sleep onset insomnia.Randomized
placebo controlled.Dose finding
Introduction
Prevalenceofchronic sleeponsetinsomniainthe nondisabled
school-aged population is approximately 10% (Blader et al.
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DOI 10.1007/s00213-010-1962-01997). A chronically reduced sleep due to insomnia may
induce various cognitive and behavioral problems in
children as well as more widespread difficulties within
their families (Dahl 1996;B l a d e re ta l .1997;R i n ge ta l .
1998). It has even been suggested that the current
attention-deficit hyperactivity disorder (ADHD) epidemic
might partly be attributable to delayed sleep phase
disorder, due to a shared underlying pathophysiology or to
misinterpretation of daytime consequences of insomnia as
ADHD symptoms (Szeinberg et al. 2006).
Chronic sleep onset insomnia in children is often
associated with a delayed time at which endogenous
melatonin concentration starts to rise in dim light (DLMO)
indicating that the biological clock rhythm in these children
is set at a later clock time than desired (Van der Heijden et
al. 2005). The DLMO is a convenient parameter, as it can
usually be obtained before—instead of during—sleep time
and is more reliable than many other endocrine or
temperature markers of the circadian pacemaker (Klerman
et al. 2002). Administration of exogenous melatonin in
children with insomnia shifts DLMO as well as sleep onset
to an earlier time in the evening, thereby ameliorating the
insomnia problems (Smits et al. 2001, 2003; Van der
Heijden et al. 2007). The direction, a phase advance or
phase delay, and the magnitude of the response of the
circadian pacemaker to exogenous melatonin depends on
the timing of administration of melatonin relative to the
rhythm phase of the pacemaker, the so-called phase
response curve. The phase response curve illustrates that
the largest phase-advancing therapeutic effects of melatonin
can be expected when administration occurs approximately
5 to 6 h before the individual DLMO. Lewy et al. (2004)
were the first to describe this in blind people with a free-
running sleep–wake rhythm. Van der Heijden et al. (2005)
demonstrated that the earlier (within a window of 3/4–6h
before DLMO) melatonin is administered in children with
sleep onset insomnia and normal vision, the larger the
phase advance of sleep onset is.
Since melatonin administration in the afternoon has the
potential to cause undesired direct soporific effects,
administration in children usually takes place in the early
evening, preferably not earlier than 18 h. Most studies
apply a melatonin dosage of 5 mg, although melatonin
plasma concentrations in children are generally higher than
in adults due to the fixed size of the pineal gland in humans
during development, while the body volume increases
(Waldhauser et al. 1988; Schmidt et al. 1995; Griefahn et
al. 2003). Children metabolize melatonin, however, more
quickly than adults (Cavallo and Dolan 1996; Cavallo and
Ritschel1996). Consequently, the dose–response relationship
of melatonin in children may differ from that in adults.
Several small studies and case reports on the efficacy of
melatonin for childhood insomnia have been published,
with pharmacological doses of 2–12 mg. These studies
showed that melatonin treatment is effective and safe in
children with sleep onset disorders with or without co-
morbidity (Jan et al. 1994, 2000; McArthur and Budden
1998; Jan 2000; Smits et al. 2001, 2003; Coppola et al.
2004; Weiss et al. 2006; Van der Heijden et al. 2007;
Wasdell et al. 2008). The applied dosage of melatonin in
these studies is very diverse, and—except in one study (Van
der Heijden et al. 2007)—not adjusted to age or bodyweight.
This is at least exceptional, in comparison to other drug
regimens in children. Most drugs are dosed in children in
relation to their bodyweight.
Recently, several reviews concluded that melatonin is
effective and safe in children irrespective of the dosage
(Pandi-Perumal et al. 2007; Owens and Moturi 2009;
Bendz and Scates 2010). So, a knowledge gap remains as
to the dosage of melatonin in children. The aim of the
present trial was to assess the dose–effect relationship of
melatonin in advancing the sleep–wake rhythm in elementary
school children aged 6–12 years suffering from chronic sleep
onset insomnia and to find the most appropriate dosage with
the largest effect and least adverse events.
With the results of a trial of short length and noninvasive
measurements, we intend to contribute to evidence-based
medicine and, therefore, to rational drug prescription in
children (Sutcliffe and Wong 2006; Vitiello 2007) suffering
from insomnia, finding the appropriate dosage of melatonin.
Methods and materials
Study design
The trial consisted of two consecutive periods: a 1-week
qualification period and 1 week of treatment, in which
participants were randomly and evenly allocated to one of
the doses of melatonin or to placebo.
The trial was performed according to the 1997 European
Guidelines for Good Clinical Research Practice in children
and followed the 1983 revised provisions of the 1975
Declaration of Helsinki.
The protocol was approved by the institutional review
board as a mono-center trial by the Central Committee on
Research Involving Human Subjects and registered in the
International Standard Randomized Controlled Trial Number
Register (ISRCTN20033346).
Participants
Children who suffered from chronic sleep onset insomnia
were referred by their general practitioner, pediatrician, or
child psychiatrist to the Centre for Sleep–Wake Disorders
and Chronobiology of the Hospital Gelderse Vallei Ede.
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suffering from sleep onset insomnia more than four nights
a week for more than 1 year, and insufficiently responded
to sleep hygiene improving measures based on parental
reports. Sleep onset insomnia was defined as sleep onset
later than 8:30 p.m. in children aged 6 years and for older
children 15 min later per year until age 12 (10:00 p.m.).
Furthermore, the latency between lights-off time and sleep
onset (sleep onset latency) had to be more than 30 min on
average. Their sleep onset had not been advanced sufficiently
with the usual sleep hygiene improving measures (Lam and
Mason 2007). Further inclusion criteria were normal sleep
architecture as indicated by a normal hypnogram, performed
within 2 months prior to participation, and written informed
consent obtained from parents. Exclusion criteria were
chronic sleep onset insomnia due to psychiatric or pedagogic
problems, known intellectual disability, pervasive develop-
mental disorder, chronic pain, known disturbed hepatic or
renal function, epilepsy, prior use of melatonin, and use of
stimulants, neuroleptics, benzodiazepines, clonidine, antide-
pressants, hypnotics, or beta-blockers within 4 weeks before
enrollment.
Finally, DLMO was determined by saliva measurements
before inclusion as described elsewhere (Nagtegaal et al.
1998) to validate the diagnosis of DSPD.
Interventions
During the treatment week, all participants took medication
on nights 1–6 between 17:30 and 19:30, placebo or melatonin
0.05or0.1or0.15mg/kg(constitutingfourtreatmentgroups).
The children and their parents were instructed to administer
the trial medication every day at the same time, depending on
age and designated bedtime. For practical reasons, we aimed
at 1.5–2 h before bedtime. This way, we ensured to be in the
previously mentioned timeframe of preferred time of
administration (TOA). The time of administration was
recorded in the sleep diary every evening.
Participants were not allowed to have their co-
medication changed. Both weeks had to be regular school
weeks, at least 2 weeks after time-shift weeks (summertime/
wintertime), and preferably without parties, school camps,
holidays, etc.
Compliance of the medication was assessed by counting
the number of capsules returned.
Outcomes
Sleep: sleep onset, sleep onset latency, wake-up time,
and total sleep time
During the baseline and treatment periods, the parents
recorded lights-off time, sleep onset, and wake up time
daily in a sleep log (on paper or online in a specialized
internet software application (Medsys/De Nieuwe Coster/
2004)); additional information on mood and adverse events
were also recorded.
During all 14 days of the trial, participants were instructed
to wear an actigraph (Cambridge Neurotechnology) from the
moment they went to bed until the moment they got up in the
morning (get-up time). This motion-sensing device—the size
of a normal wristwatch—was attached to the non-dominant
wrist. Actigraphic monitoring measured movements in 30-s
periods. It is a validated method to assess sleep patterns in
children (Morgenthaler et al. 2007; Werner et al. 2008).
Actigraphic data were converted into sleep parameters by the
validated automatic Actiwatch scoring algorithm, combined
with subsequent manual verification based on sleep log-
derived bedtime and get-up time (Kushida et al. 2001). Sleep
onset (SO) and wake-up time, as derived from the wrist
activity records, averaged over three to seven nights of each
week and were estimated as described elsewhere (Littner et
al. 2003). Sleep onset latency (SOL) and total sleep time
(TST) were calculated (SOL=SO−bed time and TST=wake
up time−SO). Sleep log data were used to validate the
actigraphy data; in case of discrepancy, the actigraphy data
prevailed.
Dim light melatonin onset
On the last nights of the baseline and the treatment week, five
saliva samples were collected by chewing on a cotton plug
during 1 min (Salivetten, Sarstedt Nümbrecht, Germany) at
19:00, 20:00, 21:00, 22:00, and 23:00 h. In the treatment
week, at this night, no trial medication was used. Salivary
melatonin concentrations were measured as described else-
where (Nagtegaal et al. 1998). To prevent suppression of
melatonin secretion by bright light (Bojkowski et al. 1987)
during the collection period, the children were instructed to
stay in bed or in the living room, with closed curtains and
only dim light allowed, 40 lx (Brainard et al. 2000). DLMO
was defined as the time at which salivary melatonin
concentration reaches 4 pg/ml and was calculated by linear
interpolation between the two samples just below and just
above 4 pg/ml.
Sample size
Based on results of a previous study of melatonin in a
similar population (Smits et al. 2001), sample size
calculation with the SPSS Sample Power 2.0 program
showed that 26 subjects in the melatonin-treatment group
and 26 subjects in the placebo-treatment group are needed
to find a significant (p<0.05; power 0.90; one tailed)
advance (SD) sleep onset of 67 (85) min compared to an
advance (SD) of 10 (46) min in the placebo group. When
Psychopharmacology (2010) 212:379–391 381four subjects have to be excluded in each treatment group,
30 subjects can be considered to be enough to find a
significant advance of sleep onset time. For four treatment
groups, the planned sample size was 120 participants to be
recruited within 3 years.
Randomization
For this trial, a specialized internet software application
(Medsys/De Nieuwe Coster/2004) was developed for
randomization of participants, for calculation of the
assigned dose (based on body weight), and for collection
of sleep log data.
Patients were randomized in blocks of eight to keep
possible seasonal time effects to a minimum.
During a visit with the neurologist, eligible patients were
invited to participate in Meldos and, if willing, added to the
database Medsys. Afterwards, the hospital pharmacist made
a telephone call to check willingness, to make an
appointment, and to randomize participants in Medsys.
For this appointment, the hospital pharmacy prepared the
appropriate trial medication and programmed the actigraph.
During the visit, the hospital pharmacist handed over all
materials (actigraph, salivettes, medication, and sleep log)
and gave instructions.
Blinding
Theassigneddoseofmelatoninwasadhocpreparedbyoneof
thehospitalpharmacytechniciansincapsules,containingonly
microcrystalline cellulose (Bufa, Haarlem, The Netherlands)
as placebo or containing melatonin (melatonin supplied by
Pharma Nord, Denmark) in the appropriate calculated dosage
and microcrystalline cellulose. The capsules were packed in
unit dose strips, labeled with “Melatonine×mg” masked with
an X to keep participants blind to the treatment allocation and
subject number.
All participants, care providers, and investigators involved
in the study were unaware of the treatment allocation.
Data analysis
The time measurements bed-, sleep onset, wake-up, and
get-up time was expressed in 24 h/min.
The difference (shift) betweenbaselineandtreatment week
for DLMO and mean sleep measures (SO, SOL, and TST)
was calculated for each participant individually.
This way, we assessed individual responses to one of the
treatments. These shifts were expressed in hours minute or
minutes alone and the means per treatment group (mean
(±SD)) were compared.
Comparisons of demographic and clinical characteristics
between treatment groups were conducted using independent
samples Student’s t test for continuous variables with a
normal distribution and Mann–Whitney U test when
distribution was not normal, using SPSS 15.0 for Windows
(SPSS Inc. 2006).
We wanted to differentiate between dosing effects and
timing effect in the observed baseline-treatment week shifts
of DLMO, SO, and SOL. Second-degree polynomial trend
line estimation in Microsoft Office Excel 2003 (Microsoft
Inc 1985–2003) and quadratic curve fit and two-tailed
correlation analysis (Pearson and Spearman’s rs; SPSS
15.0) were used to assess timing effect. We studied all shifts
as function of clock TOA and as function of circadian
TOA. The circadian TOA is determined by defining DLMO
as CT14 (Lewy et al. 1999); a clock TOA 2 h before
DLMO means a circadian TOA of CT12.
Additionally, shifts of DLMO, SO, and SOL were
studied in relation to the baseline individual circadian
alignment, characterized by the phase angle difference
(PAD). PAD reflects the time distance between baseline
DLMO and baseline mid-time of sleep measured by
actigraphy (Lewy et al. 2006).
We first analyzed the effect of melatonin treatment
(different dosages) compared to placebo. Then, we analyzed
the differences between the different melatonin dosages. The
latter analyses required exclusion of the placebo group as a
considerable part of the correlation between dosage and
outcome parameters is due to the difference between placebo
and melatonin and not to differences between the different
dosages of melatonin.
Wake-up time and total sleep time data are not analyzed
since those data were found to be strongly influenced by
fixed wake-up time.
Results
Baseline demographic and clinical characteristics
Initially, 88 children were found eligible to participate in
this study. Due to several reasons (logistic problems due
to shortage of actigraphs, holidays, social activities, attending
high school, winter/summertime shift, unexpected family
circumstances, and not allowed-co medication), 16 children
were excluded before randomization (Fig. 1).
Based on the results of interim analyses of data of the 72
included children during a period of almost 3 years, the
decision was made to finish recruitment instead of extending
the trial over a longer period of time. The trial was conducted
between May 2004 and February 2007.
Table 1 shows demographic characteristics of participants
per treatment group, including bed and medication times; the
participants were encouraged not to change bedtime and get-
up time during the 2 weeks.
382 Psychopharmacology (2010) 212:379–391The mean (±SD) bedtime, measured by actigraphy,
averaged over the four treatment groups was 20:41
(±0:41)h in the baseline week and 20:33 (±0:33)h in the
treatment week. Mean get-up time was 07:40 (±0:23)h at
baseline and 07:39 (±0:25)h in the treatment week. Both
weeks are comparable in events (ordinary [school] weeks,
no special days or activities); observed effects on sleep
parameters can, therefore, be attributed to the melatonin
administration. Get-up time was for most days, and most
children clearly restricted due to school times and,
therefore, excluded from evaluation as a treatment result.
At baseline, there were no significant between-group
differences in demographic variables.
Seventy-two children were randomized to one of the four
treatment arms. Actigraphic data were collected from 67
participants, and DLMO was dete r m i n e di n6 2p a r t i c i p a n t s .
Two children ended participation after randomization but
before the start with the trial medication: one boy because his
mother was concerned that he would see the actigraph as a
challenge to stay awake as long as possible, the second child
because of diagnosis of mononucleosis infectiosa, just prior to
starting.
Three children forgot to wear the actigraph the second
week and were, for that reason, excluded from actigraphic
data analysis.
The analysis was based on 5.3 (±0.87) nights (mean (±SD)).
Two children forgot to collect saliva samples and were, for
that reason, excluded from DLMO analysis. Additionally, in
six children, the DLMO could not be calculated because the
first salivary level at 19:00 h was already higher than 4 pg/ml
(DLMOreached),resultinginblankvalues.Thefivecollected
saliva samples were not suitable for determination of
individual thresholds like Voultsios and Burgess did (Voultsios
et al. 1997;B u r g e s se ta l .2008) as the timing was aimed at
Fig. 1 Randomization scheme and justification of obtained outcome data (per group actigraphy and DLMO data obtained within the same group
of included participants)
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traditional definition of DLMO (saliva 4 pg/ml).
The parents of 25 (35%) children did report most results
online; the other parents filled in the print out. These data
were added to the database afterwards.
Seventy-two children received seven capsules each. Two
children returned the medication unused. One child returned
two capsules because his mother decided to advance the
second DLMO test due to bedwetting (three nights in a row).
Eight children returned zero capsules: five because of
postponing the final DLMO test for social reasons, three
because the remaining capsule was used afterwards because
its effect was much appreciated.
TOA, as daily recorded in the sleep diary, was related to
age and varied between 17:58 and 20:42 h (mean 19:08±
0:34 (SD); Table 1).
Co-medication
Ten participants reported use of co-medication during the
trial, two in groups 1 and 4 and three in groups 2 and 3.
Four participants used anti-histaminics: desloratadine,
ketotifen, levocetirizine, hydroxyzine; five participants
used methylphenidate. One participant used fluticason
and salbutamol by inhalation, and one participant used
valproic acid, trimethoprim, and lactitol.
Group 1 2 3 4
Dose (mg/kg) 0.05 0.1 0.15 0
n 16 19 18 17
Bodyweight Mean 32 31 29 27
Min 18 16 16 20
Max 45 49 42 35
S D 887 4
Dose Mean 1.60 2.91 4.39 0
Min 0.9 1.4 2.4 0
Max 2.2 4.9 6.3 0
SD 0.39 0.91 0.98 0
Age Mean 9.5 8.9 8.7 8.7
Min 6.9 6.5 6.0 6.2
Max 11.7 11.6 11.3 11.8
SD 1.8 1.4 1.4 2.8
Boys (%) 9 (56%) 5 (26%) 10 (56%) 6 (35%)
Bedtime week 1 Mean 20:52 20:48 20:38 20:27
Min 19:03 19:49 19:56 19:25
Max 22:40 22:06 21:26 21:40
SD 0:59 0:34 0:28 0:34
Bedtime week 2 Mean 20:44 20:35 20:26 20:25
Min 19:13 19:58 19:25 19:35
Max 21:34 21:21 21:14 21:02
SD 0:50 0:26 0:26 0:24
Clock TOA Mean 19:15 19:08 19:11 18:59
Min 17:58 18:15 18:30 18:08
Max 20:17 20:42 20:20 20:00
SD 0:41 0:36 0:32 0:25
Get-up time week 1 Mean 7:41 7:41 7:41 7:38
Min 7:14 7:11 7:14 7:17
Max 9:18 8:55 8:24 8:09
SD 0:32 0:25 0:18 0:16
Get-up time week 2 Mean 7:39 7:41 7:32 7:48
Min 7:01 7:11 6:53 7:05
Max 8:36 8:47 8:31 8:33
SD 0:25 0:26 0:26 0:24
Table 1 Demographic
characteristics of participants
TOA time of administration
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DLMO was delayed by 16 min in the placebo group and was
advanced by 50–90 min in the melatonin treatment groups.
SO was advanced by 9 min in the placebo group and 51–
66 min in the melatonin treatment groups. SOL was reduced
by 12 min in the placebo group and by 43–54 min in the
melatonin treatment groups.
Table 2 shows the comparison of three melatonin
treatments (0.05, 0.1, and 0.15 mg/kg) with placebo.
The DLMO advance in the 0.1 and 0.15 mg/kg
treatment group was significantly (p<0.001) different
from placebo; the 0.05 mg/kg group did not reach
significance (p=0.053).
SO advanced in all three melatonin groups compared to
placebo; the SO shift difference between melatonin treat-
Table 2 Comparison of DLMO and sleep measures sleep onset and sleep onset latency between the three melatonin dosage groups and placebo
Dose Mean difference in comparison to placebo group
a Standard error of the difference 95% Confidence
interval of the
difference
df p Value
mg/kg h:m h:m Lower Upper
0.05
DLMO shift 1:05 0:32 −0:01 2:12 22.6 0.053
SO shift 0:42 0:10 0:20 1:03 29.6 <0.001
SOL shift 0:31 0:10 0:09 0:54 29.6 0.007
0.1
DLMO shift 1:45 0:26 0:53 2:38 29.0 <0.001
SO shift 0:50 0:11 0:27 1:13 29.6 <0.001
SOL shift 0:36 0:10 0:15 0:57 30.7 0.001
0.15
DLMO shift 1:31 0:24 0:41 2:21 30.7 <0.001
SO shift 0:56 0:10 0:34 1:18 29.7 <0.001
SOL shift 0:42 0:09 0:22 1:02 31.5 <0.001
Equal variances not assumed
DLMO dim light melatonin onset, SO sleep onset, SOL sleep onset latency
aPositive value=phase advance, negative value=phase delay
Fig. 2 a DLMO (threshold=4 pg/ml) advance (individual differences
between baseline and treatment week) in the four treatment groups. b
SO shift (individual differences between baseline and treatment week)
in the four treatment groups. c SOL reduction (individual differences
baseline and treatment week) in the four treatment groups. Solid box
upper and lower quartiles, box length contains the middle 50% of the
data (IQR); line median, lines extending from box (whiskers) the
distance to the largest and smallest observations that are less than one
quartile range from the box, dots O outliers (>1.5×IQR)× =extremes
(>3×IQR). DLMO dim light melatonin onset, SO sleep onset, SOL
sleep onset latency
Psychopharmacology (2010) 212:379–391 385ment and placebo treatment is 42–56 min, which is
significant (p<0.001) for all melatonin groups.
SOL was reduced in all three melatonin groups
compared to placebo. The difference between placebo
treatment and melatonin treatment for SOL shift was 31–
42 min, and the reduction of SOL differed significantly in
all three treatment groups from placebo (p=0.007,
p=0.001, and p<0.001).
Dose–response relationship versus time–response
relationship
The shifts of DLMO, SO, and SOL are visualized in
Fig. 2a–c.
Because no clear dose–response relationship was
detected in all groups, the individual time of administration
of melatonin relative to baseline DLMO were calculated
(circadian TOA). Shifts of DLMO, SO, and SOL in the
three groups with melatonin were plotted as function of
clock TOA (Fig. 3a) and as function of circadian TOA
(Fig. 3b). These figures demonstrate the relationship of the
DLMO shift with circadian TOA and not with clock TOA.
On the contrary, for SO and SOL shifts, the TOA
relationship does not show distinct differences between
clock TOA and circadian TOA.
PAD was significantly correlated to the DLMO shift, but
not to the SO and SOL shift (Fig. 4).
Curve fitting of DLMO shift (of the three melatonin
groups) with TOA expressed in relative Circadian Time,
with DLMO (CT14) as reference point=0 according to
Burgess et al. (2008)r e s u l t e di nt h es m a l lp a r to ft h e
expected PRC of melatonin (R
2=0.175, p=0.015;
Fig. 5a). Dosage differentiation did not result in distinct
curves due to the small number of subjects per dose
(n=16–19).
Curve fitting of SO shift versus TOA in relation to
baseline DLMO resulted in distinct curves for all groups
(Fig. 5b). For the higher doses, a bigger shift was noted
with an early TOA; for the TOA closer to the DLMO, this
dose relationship disappeared.
Fig. 3 a DLMO, SO, and SOL
shifts with clock TOA in the
three melatonin-treatment
groups. b DLMO, SO, and SOL
shifts with circadian TOA in the
three melatonin-treatment
groups
386 Psychopharmacology (2010) 212:379–391In the bivariate correlation analysis, the dose was
significantly correlated with all outcome parameters
(DLMO, SO, and SOL shift), as was the circadian TOA,
when tested in all treatment groups.
DLMO shift was correlated with SO shift and SOL shift
as well (Spearman correlation rs=0.38, p=0.003 and rs=
0.36, p=0.05). None of the sleep outcome parameters
appeared to be significantly related to clock TOA, in contrast
to the circadian TOA.
After exclusion of the placebo group from analysis,
correlation of all sleep parameters with dosage disap-
peared, as did the previous association of the DLMO
s h i f tw i t hS Os h i f ta n dS O Ls h i f t( T a b l e3). After
exclusion of placebo, correlation between SO shift and
clock TOA became significant, in addition to the relation
with circadian TOA. For SOL shift, exclusion of the
placebo group resulted in an additional correlation with
clock TOA and in disappearance of the correlation with
the circadian TOA. All correlations with TOA are
negative, indicating a larger shift when medication is
taken earlier.
DLMO shift was significantly correlated to PAD and
circadian TOA, and not to clock TOA (Table 3).
Adverse effects
The most common adverse events were red cheeks, red
earlobes, and red eyes and yawning within an hour after
administration (n=15); pale looks, dizziness, and cold
feelings (eight); headache (two); nausea and stomachache
(one); and dizziness and nausea (one). Most of the adverse
events wore off during the treatment week. Headache and
stomachache were reported in the placebo group, not in the
melatonin-treatment groups. The sleep-related adverse
events (red cheeks or rather pale looks, cold feelings) and
dizziness were reported in the three melatonin groups; the
frequency was related to dosage (0.15:0.1:0.05=5:4:3). One
participant ended the treatment period early due to
bedwetting, attributed to the medication by his mother
(0.05 mg/kg). Two other participants reported enhanced
urination during the evening and night (0.1 and 0.15 mg/kg).
Discussion
In children with chronic sleep onset insomnia, 1-week
treatment with melatonin significantly advanced sleep onset
and dim light melatonin onset by approximately 1 h and
reduced sleep onset latency by approximately 35 min,
compared to placebo. Surprisingly, there was, within the
dosage range of 0.05–0.15 mg/kg, no dose–response relation-
ship of melatonin and shifting of the sleep parameters or
DLMO.
It is unlikely that the treatment duration of 1 week was
too short to show differences in the efficacy between
dosages. Data from earlier studies of melatonin effects on
sleep parameters with duration of 5 weeks showed that as
early as after the first treatment night, robust treatment
effects emerged and that the effects remained stable during
the following weeks (Van Geijlswijk et al. 2010).
There may be a point of diminishing returns at a dosage
lower than the tested lowest dosage of 0.05 mg/kg. Hence,
each additional increase in dosage beyond this dosage
yields less and less additional response, until reaching a
“ceiling effect,” like the upper right part of a traditional
dose–response curve. Another possibility is that the dose–
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Fig. 4 DLMO, SO, and SOL
shifts with PAD in the three
melatonin-treatment groups
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That is, all dosages above a certain threshold dose induce
similar magnitudes of responses, like the acetylcholine
receptor-mediated innervations of motor cells (Ruff 1998).
The absence of a dose–response relationship in this study is
in line with findings in a sleep–EEG study where melatonin
was administrated at 18:00 h in the dose range of 0.5–10 mg
in six healthy adults (Stone et al. 2000).
In contrast, the timing of drug administration seems to
have substantial influence on the treatment effect. TOAwas
recorded daily; the naturalistic design of this study allowed
for some flexibility on this aspect. As a result of this, the
average TOA on Friday and Saturday was later than the
TOA on weekdays. When correcting for circadian TOA,
the differences between the 0.05 mg/kg group and the other
two dosing groups for mean DLMO shift disappear. This is
at least partly due to the considerably wider range of
DLMO–TOA interval values in the 0.05 mg/kg group
that can be attributed to the extreme minimum and
maximum results of the DLMO shift ([−2.04]–4.18)
within this group.
From a pharmacokinetic point of view, one could argue
that the lower the dosage, the shorter the interval between
TOA and DLMO should be since melatonin has a very
short elimination half-life in most individuals (between 35
and 45 min). Recently, the association between time of
administration and dosage in relation to endogenous
melatonin onset is made (Burgess et al. 2008). It is
plausible that very low dosages (0.5 mg or less) given
early (5 h before DLMO) are already cleared to below
physiological levels before endogenous melatonin onset
occurs, and we expect that no shift of DLMO will be
observed (Burgess et al. 2008). This phenomenon might
also have contributed to the nonsignificant DLMO shift
observed in the 0.05 mg/kg group, since the maximum of
DLMO–TOA interval was similar (low dosage to high
dosage 3.27, 3.55, and 3.17 h) in all melatonin groups.
SO was significantly advanced by administration of
exogenous melatonin. The magnitude of effect was not
predicted by dosage but was significantly related to clock
TOA and to circadian TOA. Especially, the correlation with
clock TOA could imply that the effects on SO and SOL that
Fig. 5 a DLMO shift
(individual differences between
baseline and treatment week)
with TOA related to baseline
DLMO, for all groups, plotted
on top of a 24-h phase response
curve adapted from Burgess et
al. (2008). b SO shift (individual
differences between baseline
and treatment week) with TOA
related to baseline DLMO in all
treatment groups
388 Psychopharmacology (2010) 212:379–391we measured were induced by the direct soporific effects of
melatonin rather than by a chronobiotic effect, comparable
to the way traditional sedatives act.
There is a methodological difference between measuring the
DLMO shift and measuring SO and SOL shifts. Post-treatment
DLMOs are determined after a period of melatonin adminis-
tration; but on the night of melatonin measurements, no
exogenous melatonin is administrated. The DLMO shift is,
therefore, not influenced by direct effects of administrated
melatonin. This isincontrastto theeffectsonSOshiftandSOL
shift, which are influenced by melatonin administration on the
measurement nights. This might explain the relationship of
PAD with DLMO shift, and not with SO and SOL shift, the
DLMO shift reflecting exclusively chronobiotic effects. The
soporific effect of melatonin improves SO and reduces SOL,
which is why individuals with a PAD ≥6 still experience a SO
and SOL shift, without a DLMO shift.
The children included all had late DLMOs. A long
TOA–DLMO interval in this population will result in a
large response to melatonin therapy, in DLMO shift, which
is a demonstration of the chronobiotic mechanism, and in
SO and SOL shift. In addition to the chronobiotic effect,
soporific effects of melatonin will add to the size effect on
SO and SOL. The effect of the same dosage of exogenous
melatonin on SO in a normal population can be completely
different since this DLMO–TOA interval will be shorter
when taken at the same clock TOA. Melatonin administra-
tion at the TOA of traditional hypnotics confers risk for the
TOA being later than DLMO, thus minimizing the potential
for phase advancing the rhythm (Fig. 5a). This may be the
mechanism behind the inefficacy of melatonin as an ordinary
hypnotic. When timing is correct, the magnitude of effect on
SO, SOL, and DLMO is not related to the dose in the
threefold dose range we have studied. This supports earlier
findings stressing the importance of measuring DLMO
before starting melatonin treatment (Hoebert et al. 2009).
A number of potential limitations need to be noted. First,
this trial assessed the effects of only 1-week treatment with
melatonin. In children with sleep onset insomnia using
melatonin, drug-holiday breaks during 1 week result in
return of the former sleep pattern in more than 90% of the
users (Hoebert et al. 2009). This implies that the chrono-
biotic effect can only be sustained with chronic treatment,
although in children, the need for advancing sleep onset
disappeared in 8% of the children after 4 years of treatment
(Hoebert et al. 2009). For the report of adverse events,
long-term studies need to be done. In fact, we did readdress
the participants of this trial 1.5–4.6 years after inclusion and
evaluated their experiences with prolonged therapy. We will
report on this soon.
Second, the groups are small, 16–19 observations per
group. Additionally, third, we should interpret all outcomes
after correction for the multiple statistical comparisons of
DLMO, SO, and SOL with the standard Bonferroni
procedure. This procedure is under discussion for its
usefulness and limitations, especially in small-numbered
studies like this (Nakagawa 2004).This is why we finally
decided to report all p values instead of reporting
significance categories. Fourth, TOA in this study neither
depended on applied dosage nor DLMO; TOA was
determined in a naturalistic way instead. This caused a
wide range of DLMO–TOA intervals, which might have
hampered the effects, especially of the lowest dosage. Due
to the double-blind dose assigning, a dose-related TOA was
not even possible. In future study design, this relationship
should be taken into account; for instance with lower doses,
a smaller DLMO–TOA interval is strived for.
Strength of the present study is that we studied
individual responses. This differs from most melatonin
trials, where response consisted of the shift of means of the
different treatment groups. We applied a naturalistic design
for timed melatonin administration, related to desired
Dosage PAD Clock TOA Circadian TOA DLMO shift SO shift
PAD 0.16
p=0.13
Clock TOA −0.05 −0.18
p=0.37 p=0.11
Circadian TOA −0.10 −0.65 −0.32
p=0.26 p<0.001 p=0.012
DLMO shift 0.15 0.37 −0.09 −0.33
p=0.16 p=0.005 p=0.28 p=0.022
SO shift 0.17 0.17 −0.35 −0.38 0.03
p=0.12 p=0.13 p=0.006 p=0.004 p=0.42
SOL shift 0.15 0.12 −0.32 −0.29 0.15 0.75
p=0.15 p=0.21 p=0.011 p=0.024 p=0.17 p<0.001
Table 3 Results of bivariate
correlation analysis for dosage,
PAD, TOA in clock time and in
circadian time, and shifts of
DLMO, SO, and SOL, tested for
melatonin treatment groups 1–3
(n=46–53)
Correlations with DLMO
measures (DLMO shift and
Circadian TOA) are Spearman
correlations; the others are Pearson
correlations
PAD phase alignment difference,
DLMO dim light melatonin
onset, TOA stime of
administration, SO sleep onset,
SOL sleep onset latency
Psychopharmacology (2010) 212:379–391 389bedtime, but with focus on maximizing the DLMO–TOA
interval.
The current finding, that the effects of melatonin
treatment on sleep–wake rhythm are not related to the
dosage in the pharmacologic dosing range (>0.05 mg/kg)
but rather to the time of administration relative to the
endogenous melatonin rhythm, is highly suggestive of
melatonin’s chronobiotic properties instead of primarily
hypnotic pharmacological properties.
In conclusion, we do not expect that dosages higher than
0.15 mg/kg will exert larger shifting effects (based on the
present data and our clinical experience). On the contrary, we
recommend that dosages higher than 0.05 mg/kg for children
with chronic insomnia are not necessary and probably should
be avoided. Whether clinically effective dosages should be
expected in the range achieving physiological serum levels or
at least in dosages lower than 0.05 mg/kg cannot be inferred
fromthepresentdata.Furtherdose–responsestudiesshouldbe
performed in order to find the lowest possible dosage of
melatonin in children, in combination with the most appropri-
ate time of administration. The issue of bioavailability should
be taken into account in further studies, with the sublingual
tablet with ultralow dosages as an interesting candidate.
Furthermore, additional long-term studies are needed to verify
the safety of melatonin in children in the long run.
This study demonstrates that melatonin for treatment of
chronic sleep onset insomnia in children is effective in a
dosage of 0.05 mg/kg given 1–2 h before DLMO and
before desired bedtime, resulting in 1-h shifts of DLMO
and SO and a SOL reduction by 35 min.
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